Migraine is a common episodic neurovascular brain disorder associated with increased risk
of cardio-and cerebrovascular ischemia. Migraine headache is likely caused by activation of …

Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the
pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with …

Objective Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging
treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue …

Migraine treatment has reached a new era with the development of drugs that target the
trigeminal neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. The CGRP …

Calcitonin gene‐related peptide (CGRP) is expressed throughout the CNS and peripheral
nervous system, consistent with control of vasodilatation, nociception, motor function …

Introduction Since calcitonin gene-related peptide (CGRP) plays an important role in the
pathophysiology of migraine via the activation of the trigeminovascular system, the newest …

Migraine is a complex, debilitating neurovascular disorder. Although knowledge on the main
molecular players is still incomplete, recent preclinical and clinical findings indicate that …

Migraine is the most prevalent neurological disorder worldwide and it has immense
socioeconomic impact. Currently, preventative treatment options for migraine include drugs …

Calcitonin gene-related peptide (CGRP), a neuropeptide abundant in the trigeminal system
and widely expressed in both the peripheral and central nervous systems, has recently …

The neuropeptide calcitonin gene‐related peptide (CGRP) is implicated in the underlying
pathology of migraine. Serum levels of CGRP, which are elevated during a migraine attack …